Serwis Infona wykorzystuje pliki cookies (ciasteczka). Są to wartości tekstowe, zapamiętywane przez przeglądarkę na urządzeniu użytkownika. Nasz serwis ma dostęp do tych wartości oraz wykorzystuje je do zapamiętania danych dotyczących użytkownika, takich jak np. ustawienia (typu widok ekranu, wybór języka interfejsu), zapamiętanie zalogowania. Korzystanie z serwisu Infona oznacza zgodę na zapis informacji i ich wykorzystanie dla celów korzytania z serwisu. Więcej informacji można znaleźć w Polityce prywatności oraz Regulaminie serwisu. Zamknięcie tego okienka potwierdza zapoznanie się z informacją o plikach cookies, akceptację polityki prywatności i regulaminu oraz sposobu wykorzystywania plików cookies w serwisie. Możesz zmienić ustawienia obsługi cookies w swojej przeglądarce.
BACKGROUND:The objective of this study was to determine whether the addition of low‐dose‐rate brachytherapy or androgen‐deprivation therapy (ADT) improves clinical outcome in patients with high‐risk prostate cancer (HiRPCa) who received dose‐escalated radiotherapy (RT).
METHODS:Between 1995 and 2010, 958 patients with HiRPCa were treated at Schiffler Cancer Center (n = 484) or at the University of...
BACKGROUNDAgent Orange (AO) exposure (AOe) is a potential risk factor for the development of prostate cancer (PCa). However, it is unknown whether AOe specifically increases the risk of lethal PCa. The objective of this study was to determine the association between AOe and the risk of detecting high‐grade PCa (HGPCa) (Gleason score ≥7) on biopsy in a US Veteran cohort.
METHODSRisk factors included...
BACKGROUNDGeographic barriers and limited availability of cancer specialists may influence early prostate cancer treatment options for rural men. This study compares receipt of different early prostate cancer treatments between rural and urban patients.
METHODSUsing 2004‐2006 SEER Limited‐Use Data, 51,982 early prostate cancer patients were identified (T1c, T2a, T2b, T2c, T2NOS; no metastases) who...
BACKGROUNDMen with multiple comorbidities are often overtreated for low‐risk prostate cancer, but it is unclear whether they are undertreated for high‐risk cancer, which has appreciable short‐term prostate cancer‐specific mortality. This study characterized the impact of comorbidity on treatment and survival in men with differing tumor risks.
METHODSThe researchers sampled 1482 men with nonmetastatic...
BACKGROUNDProstate‐specific antigen (PSA) testing is recommended every 6 to 12 months for the first 5 years following radical prostatectomy as a means to detect potential disease recurrence. Despite substantial research on factors affecting treatment decisions, recurrence, and mortality, little is known about whether men receive guideline‐concordant surveillance testing or whether receipt varies by...
BACKGROUNDProstate cancer treatment choices have been shown to vary by physician and patient characteristics. For patients with low‐risk, clinically localized prostate cancer, the authors examined the impact of their clinical, sociodemographic, and radiation oncologists' (RO) characteristics on the likelihood that the patients would receive combined external beam radiotherapy and brachytherapy, a...
BACKGROUNDPreliminary data suggest a potential decreased benefit of docetaxel in patients with metastatic, castration‐resistant prostate cancer (mCRPC) who previously received abiraterone acetate, a novel androgen synthesis inhibitor (ASI). Cancer and Leukemia Group B (CALGB) trial 90401 (Alliance), a phase 3 trial in patients with mCRPC who received docetaxel‐based chemotherapy, offered the opportunity...
BACKGROUNDPreclinical studies show that opioids stimulate angiogenesis and tumor progression through the mu opioid receptor (MOR). Although MOR is overexpressed in several human malignancies, the effect of chronic opioid requirement on cancer progression or survival has not been examined in humans.
METHODSWe performed a retrospective analysis on 113 patients identified in the Minneapolis VA Tumor...
Podaj zakres dat dla filtrowania wyświetlonych wyników. Możesz podać datę początkową, końcową lub obie daty. Daty możesz wpisać ręcznie lub wybrać za pomocą kalendarza.